Furthermore, in the KEYNOTE-048 trial of previously untreated patients with R/M HNSCC, an increase in cut-off point from CPS1 to CPS20 increased the 12-month OS rate in patients treated with pembrolizumab without substantial impact on OS in the chemotherapy plus cetuximab arm (2). This evidence concerns the gene CPS1 and head and neck squamous cell carcinoma.